MAP2K7 and fibrolamellar hepatocellular carcinoma: Taken together, this screening venture provides two exciting new pieces of information: inhibition of Hsp70 in conjunction with blocking the RAF-MEK-ERK kinase cascade selectively affects the growth of cells expressing a single allele of DNAJ-PKAc, and drug combinations that target DNAJ-PKAc/Hsp70 assemblies offer a therapeutic strategy for FLC that warrants further investigation.